Skip to main content

Table 4 IC50 doses of anticancer drugs in control conditions and after efflux pumps silencing

From: Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells

Anticancer drug Condition IC50 in examined cell lines [nmol]
CMT-U27 CMT-U309 P114 CMT-W1 CMT-W2
vinblastine ctrl 1 588 2 472 2 744 8 072 9 434
pgp siRNA 203*** 464*** 208*** 1 391*** 1 264***
bcrp siRNA 1 497 2 417 2 572 8 002 7 346
mrp1 siRNA 144*** 772** 756** 1 747*** 1 248***
  mrp3 siRNA 1 330 2 406 2 561 7 433 8 482
cisplatin ctrl 5 669 12 034 42 944 41 288 9 536
pgp siRNA 2 203** 8 613** 5 000*** 32 663*** 6 707**
bcrp siRNA 3 300** 8 540** 17 699*** 11 228*** 8 177*
mrp1 siRNA 1 339** 10 090* 20 348*** 29 132*** 5 695**
  mrp3 siRNA 303*** 7 301** 13 565*** 11 163*** 7 177*
cyclophosphamide ctrl 9 599 12 542 10 340 8 679 25 698
pgp siRNA 8 432 11 755 10 242 7 912 15 443
bcrp siRNA 799*** 2 086*** 5705** 2 463** 765***
mrp1 siRNA 8 762 11 307 9 955 7 247 7 000
  mrp3 siRNA 8 802 12 278 10 167 6 932 1 130
  1. IC50 doses [nmol] of anticancer drugs: vinblastine, cisplatin and cyclophosphamide in canine mammary cancer cell lines in control conditions and after silencing of efflux pumps expression. p < 0.05 was marked as *, p < 0.01 was marked as **, and p < 0.001 was marked as ***. One-way ANOVA followed by Tukey HSD post-hoc test was applied.